Next-Generation Bioconjugation: Meet the Experts

Colette Quinn, Senior Director and Portfolio Owner at Waters Corporation, frames the growing complexity of the bioconjugate landscape, from antibody-drug conjugates (ADCs) to antibody-oligonucleotide conjugates (AOCs) and bioconjugate vaccines. She introduces the panel of subject matter experts joining the discussion: Deanna Hunt, Senior Director of Business Development at KBI Biopharma, Lance Cadang, a scientist in Genentech’s Synthetic Molecule Analytical Chemistry division and Zhengqi Zhang, Associate Principal Scientist at Merck & Co. Deanna Hunt reacts to bioconjugate landscape expansion within the last five years and the demand for advanced therapies and biologics.